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Choice of the right renal replacement therapy for
severe acute kidney injury in critically ill patients has
been investigated many times in the last two decades.
Although some questions have been answered, in
current practice many different approaches are still
used in the ICU. One basic and important issue is the
frequency of renal replacement delivery: apart from
pathophysiological speculations, in terms of hard
outcomes (namely mortality and length of hospital
stay) should dialysis be delivered continuously or
intermittently? The authors of the CONVINT study
provided a (last) response to this debate: in expert
hands, the two treatments provide similar outcomes.
This study confirms previous studies and is also
important for other aspects, such as the possibility that
the two modalities are complementary and may be
indicated for different purposes.ial for delivering continuous therapies was no longerThe never-ending comparison between outcomes of inter-
mittent and continuous renal replacement therapy (RRT)
for renal support in the ICU has come to such a level of
unprecedented and unequivocal evidence [1-4] that, cur-
rently, meeting organizers might stop including this topic
in their programs. Nevertheless, many clinicians still have
concerns regarding which technique to routinely apply to
their patients. A recent trial by a multidisciplinary group
of German physicians with specific expertise in critical
care nephrology provided new data on this important field
[1]. Indeed, Schefold and colleagues conducted the ran-
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(CONVINT) comparing daily hemodialysis and postdilu-
tion continuous hemofiltration, and confirmed that hard
outcomes such as mortality, dialysis duration or length of
hospital stay are not significantly affected by the choice of
RRT modality (continuous or intermittent). They random-
ized very well-matched populations and delivered ad-
equate and intense treatments in terms of dose
prescription. Interestingly, the authors also detailed sev-
eral important secondary outcomes, such as days on RRT,
dialysis-free days, vasopressor days, days on ventilator as
well as course of urinary output, serum creatinine and
serum urea concentrations that were all similar in the two
groups.
This trial confirmed another three important aspects.
First, designing and conducting such a study is ex-
tremely difficult. As a matter of fact, the authors were
compelled to stop enrolling patients before the estimated
sample size was reached because technology and mater-
available in their center. In contrast to a pharmacological
intervention study, where the amount of study drugs
may be stored before the trial is started, when a RRT de-
vice (or procedure) evaluation is planned the study may
be concluded prematurely if the hospital stops supply of
the device.
Second, the possibility of switching one randomized
treatment to another cannot be excluded. The authors
showed that switching of modality occurred in about
20% of intermittent hemodialysis (IHD) patients due to
hemodynamic instability and/or significant fluid over-
load. In the continuous RRT group, switching of modal-
ity was indicated in 46% of cases because of repeated
filter clotting, metabolic reasons, bleeding or issues with
anticoagulation, thrombocytopenia or clinical improve-
ment. The high rate of treatment switch was a key issue
of Schefold and colleagues’ study. The possibility to
switch from intermittent to continuous treatment and
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words, expert clinicians in routine clinical practice may
conceive to combine the benefits of both modalities, tai-
loring RRT from patient to patient and from session to
session.
Finally, the time has come to conduct an equivalence
trial since no randomized controlled trial was able, so far,
to convincingly show the superiority of one modality over
the other: an important issue of equivalence trials, how-
ever, is the generally required large sample sizes [5]. The
study by Schefold and coworkers was probably signifi-
cantly underpowered to demonstrate such equivalence.
One can now conclude that no specific recommenda-
tion should be given about any superiority between IHD
and continuous RRT. Ideally, both should be available in
the ICU. On the other hand, it is our personal opinion
that if a center/institution/department has developed a
particular expertise with one modality, then an abrupt
change to another may be detrimental and is not recom-
mended: the best treatment may be the one that you
know better. One last aspect has not to be forgotten,
however: if short-term hard outcomes are not impacted
by RRT modality, the situation may be different for
long-term outcomes. It is noteworthy that IHD has been
suspected to cause long-term chronic kidney disease in
previously critically ill acute kidney injury patients. At
least two recent persuasive studies launched an import-
ant alarm signal [6,7]: compared with continuous RRT,
initiation of IHD in critically ill adults with acute kidney
injury is associated with a higher likelihood of chronic
dialysis. If this was confirmed, IHD as a first-line treat-
ment in the ICU should be reserved for acute or chronic
patients or for those who are less likely to be weaned
from RRT.
In conclusion, during continuous RRT and in the ab-
sence of citrate anticoagulation [8] the circuit lifespan
averages 20 hours, with downtime further shortening the
daily treatment time [9]. On the other hand, one may
speculate that softer and more prolonged intermittent
dialytic sessions may reduce IHD side effects (especially
hemodynamic instability) and improve long-term out-
comes of acute kidney injury patients [10]. In the future,
to achieve the best short-term to long-term outcomes,
the two modalities may possibly meet in the middle field
of intermittent continuity.
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